Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

133.08 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 133.08
Bid (Size) 126.53 (1)
Ask (Size) 133.21 (1)
Prev. Close 133.08
Today's Range 133.08 - 133.08
52wk Range 55.25 - 173.25
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today
Via Benzinga
2 Biotech Stocks to Buy Hand Over Fist in August
Both of these biotechs are highly innovative companies. 
Via The Motley Fool

Performance

YTD
+38.32%
+38.32%
1 Month
-12.83%
-12.83%
3 Month
+0.44%
+0.44%
6 Month
+7.06%
+7.06%
1 Year
+16.65%
+16.65%

More News

Read More
Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
Via Benzinga
How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics
Via Investor's Business Daily
Smart Money Is Betting Big In SRPT Options
Via Benzinga
NASDAQ:SRPT may be ready to breakout.
Via Chartmill
26 Analysts Have This To Say About Sarepta Therapeutics
Via Benzinga
Here's How Much $1000 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today
Via Benzinga
Here's How Much $100 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today
Via Benzinga
McKesson Reports Weak Sales, Joins JFrog, Fastly, Warner Bros. Discovery And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
7 Biotech Stocks to Buy for Their Game-Changing Potential
Via InvestorPlace
Sarepta Therapeutics (SRPT) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Expert Outlook: Sarepta Therapeutics Through The Eyes Of 25 Analysts
Via Benzinga
3 Genomics Stocks That May Transform Personalized Medicine
Via InvestorPlace
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
SAVA Stock Plunges as Cassava Sciences CEO Steps Down. What to Know.
Via InvestorPlace
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
Via Benzinga
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
From Cassava Sciences, Inc.
Via GlobeNewswire
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
Via The Motley Fool
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
Via The Motley Fool
Exposures Product Safety
1 Soaring Growth Stock to Buy and Hold for 10 Years
Via The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.